Bain Capital and Parthenon Capital plan to sell 20% to 25% equity in the medical payment technology startup Zelis, corresponding to a company valuation of about $17 billion, and have initially gained favor from medical insurance companies, payment companies, private equity funds, and sovereign wealth funds. Zelis operates a digital payment platform for medical services. Reports indicate that Zelis' business is growing, and Bain Capital and Parthenon Capital have decided to retain a portion of the equity. Goldman Sachs and JPMorgan are advisors to Bain Capital and Parthenon Capital.
贝恩资本及Parthenon拟洽售Zelis逾两成权益 公司估值约170亿美元
Bain Capital and Parthenon plan to sell over 20% of Zelis' equity, with a company valuation of approximately $17 billion.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.